These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats. Swe MT; Thongnak L; Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Lungkaphin A Clin Sci (Lond); 2019 Dec; 133(23):2415-2430. PubMed ID: 31769484 [TBL] [Abstract][Full Text] [Related]
5. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. Sa-Nguanmoo P; Tanajak P; Kerdphoo S; Jaiwongkam T; Pratchayasakul W; Chattipakorn N; Chattipakorn SC Toxicol Appl Pharmacol; 2017 Oct; 333():43-50. PubMed ID: 28807765 [TBL] [Abstract][Full Text] [Related]
6. Activation of autophagy and suppression of apoptosis by dapagliflozin attenuates experimental inflammatory bowel disease in rats: Targeting AMPK/mTOR, HMGB1/RAGE and Nrf2/HO-1 pathways. Arab HH; Al-Shorbagy MY; Saad MA Chem Biol Interact; 2021 Feb; 335():109368. PubMed ID: 33412153 [TBL] [Abstract][Full Text] [Related]
7. Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury. Tanajak P; Sa-Nguanmoo P; Sivasinprasasn S; Thummasorn S; Siri-Angkul N; Chattipakorn SC; Chattipakorn N J Endocrinol; 2018 Feb; 236(2):69-84. PubMed ID: 29142025 [TBL] [Abstract][Full Text] [Related]
8. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice. Wang D; Luo Y; Wang X; Orlicky DJ; Myakala K; Yang P; Levi M Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301371 [TBL] [Abstract][Full Text] [Related]
16. Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet-Induced Obese Mice. Sun X; Han F; Lu Q; Li X; Ren D; Zhang J; Han Y; Xiang YK; Li J Diabetes; 2020 Jun; 69(6):1292-1305. PubMed ID: 32234722 [TBL] [Abstract][Full Text] [Related]
17. The combination of dapagliflozin and statins ameliorates renal injury through attenuating the activation of inflammasome-mediated autophagy in insulin-resistant rats. Thongnak L; Pengrattanachot N; Promsan S; Phengpol N; Sutthasupha P; Chatsudthipong V; Lungkaphin A J Biochem Mol Toxicol; 2022 Apr; 36(4):e22978. PubMed ID: 34939712 [TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK/mTOR pathway. Luo J; Sun P; Wang Y; Chen Y; Niu Y; Ding Y; Xu N; Zhang Y; Xie W Eur J Pharmacol; 2021 Sep; 907():174304. PubMed ID: 34224699 [TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin Ameliorates Ovulation Disorders via Attenuating Activated Microglia-Mediated Hypothalamic Inflammation in HFD-Fed Mice. Chen X; Xiao Z; Liu Q; Luo D; Cai Y; Fan M Neuroendocrinology; 2024; 114(4):331-347. PubMed ID: 38147832 [TBL] [Abstract][Full Text] [Related]
20. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway. Meng Z; Liu X; Li T; Fang T; Cheng Y; Han L; Sun B; Chen L Int Immunopharmacol; 2021 May; 94():107492. PubMed ID: 33647823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]